Literature DB >> 26327728

Sex and Racial/Ethnic Differences in Premature Mortality Due to HIV: Florida, 2000-2009.

Mary Jo Trepka1, Theophile Niyonsenga2, Kristopher P Fennie1, Karma McKelvey1, Spencer Lieb3, Lorene M Maddox4.   

Abstract

OBJECTIVE: This study aimed to characterize premature mortality among people diagnosed with HIV infection from 2000 to 2009 in Florida, by sex and race/ethnicity, to estimate differences in premature mortality that could be prevented by linkage to HIV care and treatment.
METHODS: Florida surveillance data for HIV diagnoses (excluding concurrent AIDS diagnoses) were linked with vital records data to ascertain deaths through 2011. Years of potential life lost (YPLL) were obtained from the expected number of remaining years of life at a given age from the U.S. sex-specific period life tables.
RESULTS: Among 41,565 people diagnosed with HIV infection during the study period, 5,249 died, and 2,563 (48.8%) deaths were due to HIV/AIDS. Age-standardized YPLL (aYPLL) due to HIV/AIDS per 1,000 person-years was significantly higher for females than males (372.6, 95% confidence interval [CI] 349.8, 396.2 vs. 295.2, 95% CI 278.4, 312.5); for non-Hispanic black (NHB) females than non-Hispanic white (NHW) and Hispanic females (388.2, 95% CI 360.7, 416.9; 294.3, 95% CI 239.8, 354.9; and 295.0, 95% CI 242.9, 352.5, respectively); and for NHB males compared with NHW and Hispanic males (378.7, 95% CI 353.7, 404.7; 210.6, 95% CI 174.3, 250.8; and 240.9, 95% CI 204.8, 280.2, respectively). In multilevel modeling controlling for individual factors, NHB race was associated with YPLL due to HIV/AIDS for women (p=0.04) and men (p<0.001).
CONCLUSION: Among people diagnosed with HIV infection, females and NHB people had a disproportionately high premature mortality from HIV/AIDS, suggesting the need for enhanced efforts to improve linkage to and retention in care and medication adherence for these groups.

Entities:  

Mesh:

Year:  2015        PMID: 26327728      PMCID: PMC4529834          DOI: 10.1177/003335491513000513

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  37 in total

1.  Age adjustment using the 2000 projected U.S. population.

Authors:  R J Klein; C A Schoenborn
Journal:  Healthy People 2010 Stat Notes       Date:  2001-01

2.  Years of potential life lost (YPLL)--what does it measure?

Authors:  J W Gardner; J S Sanborn
Journal:  Epidemiology       Date:  1990-07       Impact factor: 4.822

3.  Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1999-12-10

4.  Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.

Authors:  Nancy F Crum; Robert H Riffenburgh; Scott Wegner; Brian K Agan; Sybil A Tasker; Katherine M Spooner; Adam W Armstrong; Susan Fraser; Mark R Wallace
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

5.  Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.

Authors:  H B Krentz; G Kliewer; M J Gill
Journal:  HIV Med       Date:  2005-03       Impact factor: 3.180

6.  Confidence intervals for directly standardized rates: a method based on the gamma distribution.

Authors:  M P Fay; E J Feuer
Journal:  Stat Med       Date:  1997-04-15       Impact factor: 2.373

7.  Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients.

Authors:  A D McNaghten; Debra L Hanson; Mark S Dworkin; Jeffrey L Jones
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-15       Impact factor: 3.731

8.  Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

Authors:  Kelly A Gebo; John A Fleishman; Richard Conviser; Erin D Reilly; P Todd Korthuis; Richard D Moore; James Hellinger; Philip Keiser; Haya R Rubin; Lawrence Crane; Fred J Hellinger; W Christopher Mathews
Journal:  J Acquir Immune Defic Syndr       Date:  2005-01-01       Impact factor: 3.731

9.  Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic.

Authors:  Thomas P Giordano; A Clinton White; Prasuna Sajja; Edward A Graviss; Roberto C Arduino; Ahmed Adu-Oppong; Christopher J Lahart; Fehmida Visnegarwala
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-01       Impact factor: 3.731

10.  Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy.

Authors:  Mardge H Cohen; Audrey L French; Lorie Benning; Andrea Kovacs; Kathryn Anastos; Mary Young; Howard Minkoff; Nancy A Hessol
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

View more
  5 in total

1.  Trends in Racial/Ethnic Disparities Among Patients Living with HIV in Texas, 1996 to 2013.

Authors:  Sabina O Nduaguba; Kentya H Ford; James P Wilson; Kenneth A Lawson
Journal:  J Racial Ethn Health Disparities       Date:  2017-12-21

2.  Comparison of Individual and Area Level Factors Between HIV-Infected Cisgender and Transgender Individuals in Florida (2006-2014).

Authors:  K P Fennie; M J Trepka; L M Maddox; K Lutfi; S Lieb
Journal:  AIDS Behav       Date:  2016-10

3.  Comparative analyses of population-scale phenomic data in electronic medical records reveal race-specific disease networks.

Authors:  Benjamin S Glicksberg; Li Li; Marcus A Badgeley; Khader Shameer; Roman Kosoy; Noam D Beckmann; Nam Pho; Jörg Hakenberg; Meng Ma; Kristin L Ayers; Gabriel E Hoffman; Shuyu Dan Li; Eric E Schadt; Chirag J Patel; Rong Chen; Joel T Dudley
Journal:  Bioinformatics       Date:  2016-06-15       Impact factor: 6.937

4.  Neurocognitive status and risk of mortality among people living with human immunodeficiency virus: an 18-year retrospective cohort study.

Authors:  Zaeema Naveed; Howard S Fox; Christopher S Wichman; Morshed Alam; Pamela May; Christine M Arcari; Jane Meza; Steven Totusek; Lorena Baccaglini
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

5.  Geolocalization of HIV-1 subtypes and resistance mutations of patients failing antiretroviral therapy in Salvador - Brazil.

Authors:  Antonio Walter de Oliveira Filho; Carlos Brites
Journal:  Braz J Infect Dis       Date:  2017-04-05       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.